Cumulative molecular response rates by 36 months
| . | Randomized patients, % . | . | |
|---|---|---|---|
| Outcome . | Dasatinib 100 mg qd, n = 259 . | Imatinib 400 mg qd, n = 260 . | P value . |
| MMR | 69 | 55 | <.0001 |
| MR4 | 35 | 22 | .0064 |
| MR4.5 | 22 | 12 | .0007 |
| MMR by Euro score* | |||
| Low | 83 | 65 | .0068 |
| Intermediate | 65 | 57 | .1968 |
| High | 61 | 43 | .0808 |
| . | Randomized patients, % . | . | |
|---|---|---|---|
| Outcome . | Dasatinib 100 mg qd, n = 259 . | Imatinib 400 mg qd, n = 260 . | P value . |
| MMR | 69 | 55 | <.0001 |
| MR4 | 35 | 22 | .0064 |
| MR4.5 | 22 | 12 | .0007 |
| MMR by Euro score* | |||
| Low | 83 | 65 | .0068 |
| Intermediate | 65 | 57 | .1968 |
| High | 61 | 43 | .0808 |
For polymerase chain reaction–negative samples, ≥4.5-log test sensitivity was estimated if the total ABL (control gene) transcript level was ≥25 614/reaction volume complementary DNA.
MMR rates in Euro score subgroups are presented as simple rates (percentages of patients), whereas MMR, MR4, and MR4.5 rates are presented as cumulative incidence rates. Low risk, n = 170 (84 dasatinib, 86 imatinib); intermediate risk, n = 242 (121 dasatinib, 121 imatinib); high risk, n = 98 (49 dasatinib, 49 imatinib).